PT1016711E - Processo de inactivacao de virus de envelope numa preparacao viral de adenovirus - Google Patents

Processo de inactivacao de virus de envelope numa preparacao viral de adenovirus

Info

Publication number
PT1016711E
PT1016711E PT99403194T PT99403194T PT1016711E PT 1016711 E PT1016711 E PT 1016711E PT 99403194 T PT99403194 T PT 99403194T PT 99403194 T PT99403194 T PT 99403194T PT 1016711 E PT1016711 E PT 1016711E
Authority
PT
Portugal
Prior art keywords
viral preparation
virus inactivation
preparation
inactivation process
envelope virus
Prior art date
Application number
PT99403194T
Other languages
English (en)
Inventor
Gaillac David
Koehl Michel
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of PT1016711E publication Critical patent/PT1016711E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361Methods of inactivation or attenuation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361Methods of inactivation or attenuation
    • C12N2710/10363Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
PT99403194T 1998-12-21 1999-12-17 Processo de inactivacao de virus de envelope numa preparacao viral de adenovirus PT1016711E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9816147A FR2787465A1 (fr) 1998-12-21 1998-12-21 Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes

Publications (1)

Publication Number Publication Date
PT1016711E true PT1016711E (pt) 2005-02-28

Family

ID=9534248

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99403194T PT1016711E (pt) 1998-12-21 1999-12-17 Processo de inactivacao de virus de envelope numa preparacao viral de adenovirus

Country Status (11)

Country Link
US (2) US7026154B1 (pt)
EP (1) EP1016711B1 (pt)
JP (1) JP4459353B2 (pt)
AT (1) ATE280823T1 (pt)
AU (1) AU769121B2 (pt)
CA (1) CA2292922C (pt)
DE (1) DE69921435T2 (pt)
DK (1) DK1016711T3 (pt)
ES (1) ES2230820T3 (pt)
FR (1) FR2787465A1 (pt)
PT (1) PT1016711E (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1420065A4 (en) * 2001-08-02 2005-03-09 Anges Mg Inc PROCESS FOR PRODUCING INACTIVE VIRAL ENVELOPES
ES2247404T3 (es) * 2001-12-20 2006-03-01 Bavarian Nordic A/S Metodo para la recuperacion y purificacion de poxvirus de celulas infectadas.
CA2531773A1 (en) 2003-07-21 2005-02-17 Transgene S.A. Novel multifunctional cytokines
US20050197496A1 (en) * 2004-03-04 2005-09-08 Gtc Biotherapeutics, Inc. Methods of protein fractionation using high performance tangential flow filtration
AU2005229674B2 (en) * 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment
US20060130159A1 (en) * 2004-12-09 2006-06-15 Nick Masiello Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum
US7531632B2 (en) * 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
CL2008000249A1 (es) 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
AU2010206195B2 (en) 2009-01-20 2016-03-10 Transgene Sa Soluble ICAM-1 as biomarker for prediction of therapeutic response
WO2010108908A1 (en) 2009-03-24 2010-09-30 Transgene Sa Biomarker for monitoring patients
PL2419728T3 (pl) 2009-04-17 2014-05-30 Transgene Sa Biomarker do monitorowania pacjentów
JP5650212B2 (ja) 2009-07-10 2015-01-07 トランジェーヌ、ソシエテ、アノニムTransgene S.A. 患者を選択するためのバイオマーカーおよび関連方法
EP2461826A2 (en) 2009-08-07 2012-06-13 Transgene SA Composition for treating hbv infection
US9644187B2 (en) 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
EP2598223B1 (en) 2010-07-30 2022-04-06 EMD Millipore Corporation Chromatography media and method
WO2012090067A1 (en) * 2010-12-30 2012-07-05 Lfb Biotechnologies Glycols as pathogen inactivating agents
EP3587455A1 (en) 2012-10-23 2020-01-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
CN106794389A (zh) 2014-09-02 2017-05-31 Emd密理博公司 具有纳米原纤化表面特征的高表面积纤维介质
CN107001410A (zh) 2014-12-08 2017-08-01 Emd密理博公司 混合床离子交换吸附剂
CA2975432A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
CN111511800B (zh) 2017-10-30 2023-11-28 武田药品工业株式会社 灭活脂包膜病毒的环境相容性去污剂
US11690869B2 (en) * 2020-04-23 2023-07-04 Johnson & Johnson Consumer Inc. Methods of inhibiting enveloped viruses using low molecular weight hydrophobically modified polymers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378208B2 (en) * 1989-01-13 2003-01-15 Mitsubishi Pharma Corporation Production method for protein-containing composition
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
DE19623293C2 (de) * 1996-06-11 1998-10-22 Biotest Pharma Gmbh Nicht-immunogene Faktor VIII-enthaltende Zusammensetzung und ein Verfahren zu ihrer Herstellung
ATE353956T1 (de) * 1996-12-13 2007-03-15 Schering Corp Methoden zur virus-reinigung
DE19709186C2 (de) * 1997-03-06 1999-10-14 Medigene Ag Filtrationsverfahren zur Trennung von Viren

Also Published As

Publication number Publication date
US7026154B1 (en) 2006-04-11
ATE280823T1 (de) 2004-11-15
DE69921435D1 (de) 2004-12-02
US20060166345A1 (en) 2006-07-27
CA2292922A1 (fr) 2000-06-21
DE69921435T2 (de) 2006-03-02
ES2230820T3 (es) 2005-05-01
CA2292922C (fr) 2011-05-31
JP4459353B2 (ja) 2010-04-28
US7378265B2 (en) 2008-05-27
AU769121B2 (en) 2004-01-15
JP2000201673A (ja) 2000-07-25
FR2787465A1 (fr) 2000-06-23
EP1016711B1 (fr) 2004-10-27
AU6535899A (en) 2000-06-22
EP1016711A1 (fr) 2000-07-05
DK1016711T3 (da) 2005-03-07

Similar Documents

Publication Publication Date Title
PT1016711E (pt) Processo de inactivacao de virus de envelope numa preparacao viral de adenovirus
AR020054A1 (es) COMPOSICIoN QUE COMPRENDE UN ADENOVIRUS
ATE333849T1 (de) In-vitro herstellung von transplantierbarem knorpelgewebe
NZ512792A (en) Stable liquid interferon beta formulations
DE69629209D1 (de) Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose
GB2085880B (en) 1-carboxyalkanoylindoline-2-carboxylic acids process for their manufacture pharmaceutical preparations containing thhese compounds and their therapeutic application
NO993247L (no) Fremgangsmåte for fremstilling av tolterodin
ES8307500A1 (es) "metodo para inactivar los virus infecciosos contenidos en una composicion enzimatica hemocoagulante".
DE69124769D1 (de) Verfahren zur Herstellung von (1'R,3S)-3-(1'-hydroxy-ethyl)-Azetidin-2-on und deren Derivaten
PT1149910E (pt) Composicao farmaceutica contra os tumores e as infeccoes por papilomavirus
FI886050A7 (fi) Amperometrinen menetelmä 1,4-dihydronikotiiniamidiadeniinidinukleotidin (NADH) kvantitatiiviseksi määrittämiseksi liuoksessa
ATE233086T1 (de) Wirkstoffhaltige pflaster
AU7554987A (en) Solutions of oxazaphosphorins having improved stability and process for the preparation thereof
FI952482A7 (fi) Uusi menetelmä taksaanijohdannaisten valmistamiseksi, näin saadut johd annaiset ja niitä sisältävät koostumukset
IT7927440A0 (it) Enzima immobilizzato, procedimenti per la preparazione di detto enzima nonche' procedimento per effettuare una reazione enzimatica.
DE69939171D1 (de) Pharmazeutische zusammensetzungen mit tumor nekrose faktor und 2-methoxyestron-3-o-sulphamat als estrone sulphatasehemmern
ATE346859T1 (de) Zusammensetzung zum zellspezifischen transfer von wirkstoffen
DE3769691D1 (de) Substituierte oximether, ihre verwendung als bioregulatoren zur senkung des endogenen ethylenspiegels in pflanzen.
NO895002D0 (no) Enzymhemmende aminosyrederivater.
DE59909258D1 (de) Färbemittel mit enzymen
AU2979899A (en) Treatment of viral disease in swine
BR9807785A (pt) Processo para a preparação do composto, e, composto
BR9813634A (pt) "abridores de canal de potássio"
EP0836484A4 (en) In vitro packaging of adeno-associated virus dna
ATE118763T1 (de) Phenolisches amin als antimelanoma- und depigmentierungsmittel.